Prevnar 13™ + V114 + RotaTeq™ + Pentacel™ + RECOMBIVAX HB™ + HIBERIX™ + M-M-R™ II + VARIVAX™
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pneumococcal Infections
Conditions
Pneumococcal Infections
Trial Timeline
Oct 18, 2018 → Dec 14, 2020
NCT ID
NCT03620162About Prevnar 13™ + V114 + RotaTeq™ + Pentacel™ + RECOMBIVAX HB™ + HIBERIX™ + M-M-R™ II + VARIVAX™
Prevnar 13™ + V114 + RotaTeq™ + Pentacel™ + RECOMBIVAX HB™ + HIBERIX™ + M-M-R™ II + VARIVAX™ is a phase 3 stage product being developed by Merck for Pneumococcal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT03620162. Target conditions include Pneumococcal Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03620162 | Phase 3 | Completed |
Competing Products
20 competing products in Pneumococcal Infections